53 related articles for article (PubMed ID: 12696006)
1. Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection.
Yee LJ; Perez KA; Tang J; van Leeuwen DJ; Kaslow RA
J Infect Dis; 2003 Apr; 187(8):1264-71. PubMed ID: 12696006
[TBL] [Abstract][Full Text] [Related]
2. Gender-dependent association of CTLA4 polymorphisms with resolution of hepatitis C virus infection.
Schott E; Witt H; Hinrichsen H; Neumann K; Weich V; Bergk A; Halangk J; Müller T; Tinjala S; Puhl G; Neuhaus P; Wiedenmann B; Berg T
J Hepatol; 2007 Mar; 46(3):372-80. PubMed ID: 17150279
[TBL] [Abstract][Full Text] [Related]
3. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
[TBL] [Abstract][Full Text] [Related]
4. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection.
Yee LJ; Tang J; Gibson AW; Kimberly R; Van Leeuwen DJ; Kaslow RA
Hepatology; 2001 Mar; 33(3):708-12. PubMed ID: 11230752
[TBL] [Abstract][Full Text] [Related]
5. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.
Naito M; Matsui A; Inao M; Nagoshi S; Nagano M; Ito N; Egashira T; Hashimoto M; Mishiro S; Mochida S; Fujiwara K
J Gastroenterol; 2005 Apr; 40(4):381-8. PubMed ID: 15868370
[TBL] [Abstract][Full Text] [Related]
6. Correlations of CTLA-4 gene polymorphisms and hepatitis C chronic infection.
Danilovic DL; Mendes-Correa MC; Lima EU; Zambrini H; K Barros R; Marui S
Liver Int; 2012 May; 32(5):803-8. PubMed ID: 22136395
[TBL] [Abstract][Full Text] [Related]
7. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
Chu CM; Sheen IS; Liaw YF
Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
[TBL] [Abstract][Full Text] [Related]
8. Re-treatment of children with chronic hepatitis C who did not respond to interferon-alpha treatment.
Gerner P; Hilbich J; Wenzl TG; Behrens R; Walther F; Kliemann G; Enninger A; Wirth S
J Pediatr Gastroenterol Nutr; 2010 Aug; 51(2):187-90. PubMed ID: 20512050
[TBL] [Abstract][Full Text] [Related]
9. The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients.
Baur K; Mertens JC; Schmitt J; Iwata R; Stieger B; Frei P; Seifert B; Bischoff Ferrari HA; von Eckardstein A; Müllhaupt B; Geier A;
Antivir Ther; 2012; 17(3):541-7. PubMed ID: 22300961
[TBL] [Abstract][Full Text] [Related]
10. HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C.
Romero-Gómez M; González-Escribano MF; Torres B; Barroso N; Montes-Cano MA; Sánchez-Muñoz D; Núñez-Roldan A; Aguilar-Reina J
Am J Gastroenterol; 2003 Jul; 98(7):1621-6. PubMed ID: 12873589
[TBL] [Abstract][Full Text] [Related]
11. Associations between cytotoxic T lymphocyte-associated antigen-4 polymorphisms and serum tumor necrosis factor-α and interferon-γ levels in patients with chronic hepatitis B virus infection.
Han Q; Duan S; Zhang G; Li Z; Li N; Zhu Q; Lv Y; Chen J; Liu Z
Inflamm Res; 2011 Nov; 60(11):1071-8. PubMed ID: 21847627
[TBL] [Abstract][Full Text] [Related]
12. Cohort- and time-specific associations of CTLA4 genotypes with HIV-1 disease progression.
Shao W; Lazaryan A; Dorak MT; Penman-Aguilar A; Wilson CM; Margolick JB; Goedert JJ; Prins M; Tang J; Kaslow RA
AIDS; 2006 Aug; 20(12):1583-90. PubMed ID: 16868438
[TBL] [Abstract][Full Text] [Related]
13. Association of -319 C/T and +49 A/G polymorphisms of CTLA-4 gene in patients with hepatitis C virus infection.
Enciso-Vargas M; Ruíz-Madrigal B; Muñoz-Valle JF; Morales-Balderas OY; Hernández-Nazara ZH; Martínez-López E; Dávalos-Cobian C; Padilla-Gutiérrez JR; Torres-Baranda JR; Domínguez-Rosales JA; Maldonado-González M
Med Clin (Barc); 2018 Apr; 150(7):251-256. PubMed ID: 29033194
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection.
Thio CL; Mosbruger TL; Kaslow RA; Karp CL; Strathdee SA; Vlahov D; O'Brien SJ; Astemborski J; Thomas DL
J Virol; 2004 Oct; 78(20):11258-62. PubMed ID: 15452244
[TBL] [Abstract][Full Text] [Related]
15. The genetic differences with whole genome linkage disequilibrium mapping between responder and non-responder in interferon-alpha and ribavirin combined therapy for chronic hepatitis C patients.
Chen PJ; Hwang Y; Lin CG; Wu YJ; Wu LS
Int J Immunogenet; 2008 Apr; 35(2):153-7. PubMed ID: 18279371
[TBL] [Abstract][Full Text] [Related]
16. CTLA4 dimorphisms and the multiple sclerosis phenotype.
Masterman T; Ligers A; Zhang Z; Hellgren D; Salter H; Anvret M; Hillert J
J Neuroimmunol; 2002 Oct; 131(1-2):208-12. PubMed ID: 12458054
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic T-lymphocyte-associated antigen-4 single nucleotide polymorphisms and haplotypes in primary biliary cirrhosis.
Donaldson P; Veeramani S; Baragiotta A; Floreani A; Venturi C; Pearce S; Wilson V; Jones D; James O; Taylor J; Newton J; Bassendine M
Clin Gastroenterol Hepatol; 2007 Jun; 5(6):755-60. PubMed ID: 17482523
[TBL] [Abstract][Full Text] [Related]
18. The polymorphisms -318C>T in the promoter and 49A>G in exon 1 of CTLA4 and the risk of aplastic anemia in a Caucasian population.
Svahn J; Capasso M; Lanciotti M; Marrone A; Haupt R; Bacigalupo A; Pongiglione C; Boschetto L; Longoni D; Pillon M; Pistorio A; Di Michele P; Iori AP; Calvillo M; Locasciulli A; Menna G; Riccardi R; Ramenghi U; Dufour C; Iolascon A
Bone Marrow Transplant; 2005 Mar; 35 Suppl 1():S89-92. PubMed ID: 15812539
[TBL] [Abstract][Full Text] [Related]
19. Genetic analysis of interferon induced thyroiditis (IIT): evidence for a key role for MHC and apoptosis related genes and pathways.
Hasham A; Zhang W; Lotay V; Haggerty S; Stefan M; Concepcion E; Dieterich DT; Tomer Y
J Autoimmun; 2013 Aug; 44():61-70. PubMed ID: 23683877
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics of hepatitis C therapy.
Liapakis A; Jacobson I
Pharmacogenomics; 2010 Feb; 11(2):135-9. PubMed ID: 20136353
[No Abstract] [Full Text] [Related]
[Next] [New Search]
